APLS
Price
$22.49
Change
-$0.51 (-2.22%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.89B
28 days until earnings call
DNLI
Price
$12.80
Change
-$0.94 (-6.84%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2B
40 days until earnings call
Ad is loading...

APLS vs DNLI

Header iconAPLS vs DNLI Comparison
Open Charts APLS vs DNLIBanner chart's image
Apellis Pharmaceuticals
Price$22.49
Change-$0.51 (-2.22%)
Volume$44.52K
Capitalization2.89B
Denali Therapeutics
Price$12.80
Change-$0.94 (-6.84%)
Volume$20.81K
Capitalization2B
APLS vs DNLI Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. DNLI commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a StrongBuy and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (APLS: $23.00 vs. DNLI: $13.74)
Brand notoriety: APLS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 148% vs. DNLI: 298%
Market capitalization -- APLS: $2.83B vs. DNLI: $1.86B
APLS [@Biotechnology] is valued at $2.83B. DNLI’s [@Biotechnology] market capitalization is $1.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, both APLS and DNLI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 4 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а -3.32% price change this week, while DNLI (@Biotechnology) price change was -0.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

APLS is expected to report earnings on May 01, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.89B) has a higher market cap than DNLI($2B). APLS YTD gains are higher at: -27.922 vs. DNLI (-32.581). APLS has higher annual earnings (EBITDA): -154.53M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. APLS (411M). DNLI has less debt than APLS: DNLI (48.7M) vs APLS (470M). APLS has higher revenues than DNLI: APLS (781M) vs DNLI (0).
APLSDNLIAPLS / DNLI
Capitalization2.89B2B145%
EBITDA-154.53M-492.89M31%
Gain YTD-27.922-32.58186%
P/E RatioN/AN/A-
Revenue781M0-
Total Cash411M832M49%
Total Debt470M48.7M965%
FUNDAMENTALS RATINGS
APLS vs DNLI: Fundamental Ratings
APLS
DNLI
OUTLOOK RATING
1..100
1475
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
8693
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (73) in the Medical Distributors industry is in the same range as DNLI (94) in the Biotechnology industry. This means that APLS’s stock grew similarly to DNLI’s over the last 12 months.

APLS's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as DNLI (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as APLS (98) in the Medical Distributors industry. This means that DNLI’s stock grew similarly to APLS’s over the last 12 months.

APLS's Price Growth Rating (86) in the Medical Distributors industry is in the same range as DNLI (93) in the Biotechnology industry. This means that APLS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that DNLI’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEKX12.630.11
+0.88%
Baillie Gifford International Growth K
NEXIX28.94N/A
N/A
Shelton Sustainable Equity Institutional
GSXCX24.92N/A
N/A
abrdn US Small Cap Equity C
CDDRX34.31N/A
N/A
Columbia Dividend Income Inst2
VMCRX5.41N/A
N/A
Voya MidCap Opportunities Port R6

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NTLA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+1.41%
NTLA - APLS
41%
Loosely correlated
+9.69%
BEAM - APLS
40%
Loosely correlated
+4.79%
CRSP - APLS
40%
Loosely correlated
+3.17%
DNLI - APLS
39%
Loosely correlated
+11.80%
IGMS - APLS
39%
Loosely correlated
+6.96%
More